Synthesis, enzymatic inhibition, and cancer cell growth inhibition of novel δ-lactam-based histone deacetylase (HDAC) inhibitors
- 1 August 2006
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (15) , 4068-4070
- https://doi.org/10.1016/j.bmcl.2006.04.091
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 1. Design, Synthesis, Biological Evaluation, and Binding Mode Studies Performed through Three Different Docking ProceduresJournal of Medicinal Chemistry, 2003
- Histone-deacetylase inhibitors: novel drugs for the treatment of cancerNature Reviews Drug Discovery, 2002
- 25 years after the nucleosome model: chromatin modificationsTrends in Biochemical Sciences, 2000
- Histone deacetylase inhibitors: novel anticancer agentsExpert Opinion on Investigational Drugs, 1999
- Histone acetylation and cancerCurrent Opinion in Genetics & Development, 1999
- Histone acetylases and deacetylases in cell proliferationCurrent Opinion in Genetics & Development, 1999
- A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylasesProceedings of the National Academy of Sciences, 1998
- Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.Proceedings of the National Academy of Sciences, 1996
- FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice.The Journal of Antibiotics, 1994
- Solution of a classical problem. Tautomerism and isomerism in the .alpha.-methylglutaconic acid seriesThe Journal of Organic Chemistry, 1975